Diabetes therapy targeting abnormal stem cells
AssigneeBiozipcode, Inc.
InventorsHideto Kojima, Tomoya Terashima, Miwako Katagi
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiozipcode, Inc.
InventorsHideto Kojima, Tomoya Terashima, Miwako Katagi
Estimating the term…
The present disclosure provides a diabetes mellitus therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus, said therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a diagnosis of diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus or a risk of the same, said diagnosis using abnormal stem cells as an index. In one embodiment, the abnormal stem cells described in the present disclosure are abnormal hematopoietic stem cells. In one embodiment, CD106 is expressed in the abnormal stem cells described in the present disclosure at a level different from in normal cells.
-12. (canceled)
A method for treating and/or preventing diabetes mellitus or a disease, disorder, and/or symptom associated with diabetes mellitus in a subject, comprising administering an effective amount of an agent that reduces or eliminates an abnormal hematopoietic stem cell (HSC) in the subject.
A method for diagnosing diabetes mellitus or diabetes mellitus and/or a disease, disorder, and/or symptom associated with diabetes mellitus or a risk thereof in a subject, comprising detecting an abnormal hematopoietic stem cell (HSC) in the subject.
Dependencies are inferred from the claim text.